Table 5 Patient-level factors associated with receiving low-dose apixaban from the Veterans Health Administration, as compared to receiving full-dose, among those who met clinical criteria to receive full-dose apixaban for non-valvular atrial fibrillation. This table includes patients with none of the three factors suggesting a need for low-dose therapy (i.e., age < 80, serum creatinine < 1.5, and body mass > 60 kg, n = 13,162)

 ≤ 69

26.0%

44.1%

REF

 70–74

27.1%

28.0%

1.86

(1.27, 2.72)

<  0.001

 75–79

46.9%

27.9%

2.83

(1.99, 4.07)

0.001

 Female

0.8%

1.6%

0.60

(0.10, 1.94)

0.48

 Male

99.2%

98.4%

REF

 White

87.4%

86.9%

REF

 Black

6.9%

7.4%

0.97

(0.54, 1.62)

0.91

 Other

5.7%

5.8%

0.91

(0.46, 1.62)

0.77

 Northeast

11.5%

14.1%

REF

 Midwest

22.5%

25.2%

1.30

(0.80, 2.18)

0.30

 West

23.3%

20.9%

1.07

(0.64, 1.83)

0.80

 South

42.7%

39.8%

1.40

(0.89, 2.27)

0.16

 61–69

12.6%

4.8%

3.14

(2.00, 4.79)

<  0.001

 70–79

17.9%

11.5%

1.75

(1.19, 2.52)

0.003

 80+

69.5%

83.8%

REF

 Heart Failure

19.8%

14.7%

1.44

(0.99, 2.05)

0.050

 Hypertension

71.8%

73.1%

0.85

(0.58, 1.26)

0.41

 Vascular Disease

24.4%

22.2%

1.02

(0.72, 1.43)

0.91

 Diabetes

58.0%

53.2%

1.29

(0.94, 1.80)

0.12

 Prior Bleeding

4.2%

4.6%

0.84

(0.40, 1.58)

0.63

 Stroke

5.3%

7.3%

0.68

(0.36, 1.18)

0.20

 <  1

30.5%

36.5%

REF

 1.0–1.29

29.0%

29.3%

1.21

(0.87, 1.69)

0.26

 1.3–1.49

25.6%

15.6%

1.79

(1.26, 2.55)

0.001

 0–2

25.6%

27.2%

REF

 3–4

32.8%

38.8%

0.81

(0.54, 1.22)

0.31

 ≥ 5

34.4%

28.2%

1.22

(0.76, 1.95)

0.41